论文部分内容阅读
目的:探讨血清解整合素样-金属蛋白酶8、血浆M2型丙酮酸激酶检测对早期诊断非小细胞肺癌的价值。方法:用ELISA法检测72例非小细胞肺癌患者,30例良性肺疾病患者和30例健康志愿者血清中的解整合素样-金属蛋白酶8浓度和EDTA抗凝血浆中的M2型丙酮酸激酶浓度,行组间比较,以ROC曲线评价诊断价值并相互比较。结果:非小细胞肺癌组血清解整合素样-金属蛋白酶8浓度和血浆M2型丙酮酸激酶浓度均明显高于良性肺疾病组和健康对照组,差异均有统计学意义(P<0.01)。解整合素样-金属蛋白酶8、M2型丙酮酸激酶、癌胚抗原的AUC分别为0.85、0.87、0.90,诊断界值分别取328pg/mL、16.5u/mL、5ng/mL时,其灵敏度分别为76.4%、75.0%、75.0%,特异度分别为83.4%,85.0%,86.7%。结论:解整合素样-金属蛋白酶8和M2型丙酮酸激酶检测对非小细胞肺癌诊断均有较好的价值。
Objective: To investigate the value of serum unintegrin-like metalloproteinase-8 and plasma pyruvate kinase M2 in the early diagnosis of non-small cell lung cancer. Methods: Serum samples from 72 non-small cell lung cancer patients, 30 patients with benign lung disease and 30 healthy volunteers were tested for the concentration of anti-integrin-like metalloproteinase-8 and the level of pyruvate kinase M2 in EDTA anticoagulated plasma by ELISA Concentration, line group comparison, ROC curve evaluation of the diagnostic value and compared with each other. Results: Serum levels of integrin - like metalloproteinase - 8 and plasma pyruvate kinase M2 in non - small cell lung cancer were significantly higher than those in benign lung disease and healthy controls (P <0.01). The AUC values of integrin-like metalloproteinase 8, M2 pyruvate kinase and carcinoembryonic antigen were 0.85, 0.87 and 0.90, respectively. The diagnostic limits were 328pg / mL, 16.5u / mL and 5ng / mL respectively, 76.4%, 75.0% and 75.0%, respectively. The specificity was 83.4%, 85.0% and 86.7% respectively. Conclusion: The detection of integrin-like metalloproteinase 8 and M2 pyruvate kinase has a good value in the diagnosis of non-small cell lung cancer.